Oxaliplatin Phares

Oxaliplatin, the active ingredient in Oxaliplatin Phares, is a platinum‑based chemotherapy presented as a strength/form for intravenous use. It treats colorectal cancer and other solid tumours in adult patients. GNH USA supplies Oxaliplatin Phares as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Oxaliplatin Phares as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Oxaliplatin Phares is a platinum‑based chemotherapy used in the treatment of cancers that arise from the gastrointestinal tract and related pathways.

- Colorectal cancer: Improves survival rates when combined with fluorouracil and leucovorin. - Gastric cancer: Used in combination regimens for advanced disease. - Pancreatic cancer: Part of multi‑drug protocols for metastatic disease.

Oxaliplatin may elicit a range of adverse reactions, from mild to severe, depending on individual tolerance and treatment context.

Common Side Effects: - Nausea and vomiting: Frequent gastrointestinal upset during infusion. - Peripheral neuropathy: Tingling or numbness in the hands and feet. - Diarrhoea: Loose stools that may require supportive care. - Fatigue: Generalised tiredness affecting daily activities. - Myelosuppression: Decreased blood cell counts, increasing infection risk.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: Including anaphylaxis, requiring immediate medical attention. - Acute pulmonary toxicity: Shortness of breath and lung infiltrates. - Cardiac arrhythmias: Irregular heart rhythms observed during infusion. - Severe neutropenia: Markedly low neutrophil counts, raising infection risk. - Thrombotic events: Blood clot formation in veins or arteries.

When administering Oxaliplatin Phares, clinicians should observe several safety measures to minimise risks.

- Renal function monitoring: Assess baseline and periodic kidney function tests. - Pre‑hydration: Provide adequate intravenous fluids before infusion. - Neuropathy assessment: Evaluate for pre‑existing peripheral neuropathy and monitor throughout treatment. - Electrolyte balance: Correct hypomagnesemia and other electrolyte abnormalities before dosing. - Concomitant drug review: Avoid concurrent use of other neuro‑toxic agents when possible. - Store at ambient temperature: Keep in original packaging, protect from light and moisture.

Oxaliplatin can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Nephrotoxic agents: Concurrent use with high‑dose cis‑cisplatin or aminoglycosides may worsen kidney injury. - Anticoagulants: Increased bleeding risk when combined with warfarin or direct oral anticoagulants.

Moderate Interaction ​​​​​​  : - Neurotoxic drugs: Concurrent use of vin  t   t   t  t  t  ight  ight  ight \n ---

---  t  t  t  t  ight  ight  ight  t  t  t  t  ight  ight  ---  ---  ---.

The   t  t t.